Zacks: Brokerages Expect RVL Pharmaceuticals plc (NASDAQ:RVLP) Will Announce Quarterly Sales of $7.20 Million

Wall Street brokerages forecast that RVL Pharmaceuticals plc (NASDAQ:RVLPGet Rating) will post sales of $7.20 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for RVL Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $5.50 million and the highest estimate coming in at $10.50 million. RVL Pharmaceuticals posted sales of $23.88 million during the same quarter last year, which would indicate a negative year over year growth rate of 69.8%. The business is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that RVL Pharmaceuticals will report full-year sales of $58.20 million for the current financial year, with estimates ranging from $45.10 million to $73.61 million. For the next year, analysts anticipate that the company will report sales of $119.20 million, with estimates ranging from $102.30 million to $131.13 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow RVL Pharmaceuticals.

RVL Pharmaceuticals (NASDAQ:RVLPGet Rating) last posted its quarterly earnings data on Wednesday, March 30th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.03). RVL Pharmaceuticals had a negative net margin of 160.51% and a negative return on equity of 92.86%. During the same quarter in the prior year, the company posted ($0.26) earnings per share.

Several analysts have recently commented on the company. Zacks Investment Research cut RVL Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 26th. Barclays began coverage on RVL Pharmaceuticals in a report on Tuesday, April 5th. They issued an “overweight” rating for the company.

Shares of NASDAQ:RVLP traded up $0.02 during midday trading on Friday, hitting $1.72. The stock had a trading volume of 61,937 shares, compared to its average volume of 146,458. The company has a quick ratio of 2.91, a current ratio of 2.95 and a debt-to-equity ratio of 0.57. The stock has a 50-day moving average price of $1.60. The company has a market capitalization of $143.64 million, a P/E ratio of -1.81 and a beta of 1.78. RVL Pharmaceuticals has a fifty-two week low of $0.98 and a fifty-two week high of $4.85.

RVL Pharmaceuticals Company Profile (Get Rating)

RVL Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders.

Featured Stories

Get a free copy of the Zacks research report on RVL Pharmaceuticals (RVLP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for RVL Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RVL Pharmaceuticals and related companies with's FREE daily email newsletter.